- Display 30 Products per page
Published: September 1, 2009 | Price: $2,995.00 – $5,990.00
With pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the industry. Kalorama’s Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems provides detail for business planners on the market for implantable / injectable delivery system markets. Biopharmaceutical products are driving growth of needle-free systems; there will likely be significant increases in revenues in the vaccine arena. This report looks at that trend and reports...Published: October 1, 2008 | Price: $2,995.00 – $6,995.00
The strategic concept of HIV/AIDS diagnosis and therapy is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS diagnostics and therapeutics, companies must think on a global basis. In addition to the basic pathology and complications of HIV/AIDS, there are primarily three focal points for the development of strategy in this area: potential market, epidemiology (HIV/AIDS patient trends) and technology. In his report HIV Markets for...Published: April 1, 2007 | Price: $2,995.00 – $5,990.00
The market for antibiotics has changed and a knowledge of the current drug resistance situation is critical before operating in this marketplace. The effectiveness of many antibacterials (antibiotics) is being reduced as more and more types of bacteria become resistant to them. These and other developments are covered in Kalorama's Anti-Infectives, World Markets, Vol. II: Antibacterials providing extensive detail on the anti-bacterial market, including the following critical trends: Drug resistance and Interactions Antibiotic Abuse Antibiotic Cycling Addressing Market Trends Antibiotic...Published: February 1, 2007 | Price: $2,995.00 – $4,990.00
Fueled by the promise of needle-free mechanisms for vaccine distribution and other pharmaceutical uses, the implantable/injectable drug delivery market is growing rapidly. The development of better delivery systems in conjunction with the discovery of novel pharmacological compounds will lead to continued growth. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products. The implantable/injectable delivery drug market is a expected to grow to over $12 billion by 2010. Kalorama’s Drug Delivery Markets. Edition...Published: July 1, 2006 | Price: $2,995.00 – $7,800.00
Ophthalmology is entering one of the most remarkable phases in recent history of this industry; new technologies and treatment modalities for both visual acuity and major eye diseases may dramatically change the composition and competitive dynamics of this market. As RK and LASIK changed the market a few years ago, even newer competitive technologies are just now emerging. From the advent of photodynamic therapy and new drug delivery techniques to revolutionary surgical approaches to refractive vision correction, ophthalmology is poised...Published: January 1, 2006 | Price: $2,995.00 – $5,990.00
In the Spring of 2003, Kalorama published its first report on Outsourcing in Drug Discovery. Since then, so much has changed, the use of the term "2nd Edition" hardly seems appropriate. This new study involved completely re-examining the market from the ground up. This new report is designed to make readers aware of the enormous changes that are taking place in the drug discovery outsourcing market, and the forces that are shaping the sector. It presents viewpoints from both customers...Published: June 1, 2004 | Price: $2,995.00 – $5,990.00
Ten years ago, high throughput screening (HTS) was being touted as the answer to improving productivity in drug discovery. If screening thousands of compounds a week was good, screening hundreds of thousands would be even better. This led to the boom in Ultra HTS (UHTS), manufacturing-scale systems, and high-speed automation. Today, reality has begun to creep in: HTS and UHTS have not lived up to their hype. R&D productivity is not improving, in fact it may be declining. In the...Published: March 1, 2004 | Price: $2,995.00 – $5,990.00
Cardiovascular disease includes chronic conditions such as hypertension, congestive heart failure and atherosclerosis, as well as such acute conditions as myocardial infarction and cardiac arrest. While cardiovascular disease may be diagnosed at any age, it is most prevalent in later years, particularly among sedentary individuals who are also overweight or obese. With the aging of the "Baby Boom" generation, a generation that has defined the term "couch potato" and has grown up on and maintained a diet of fast-food, the...Published: January 1, 2004 | Price: $2,995.00 – $5,990.00
Type II diabetes is a metabolic disease the increases in incidence and prevalence with age. Type II diabetes (also known as "adult onset diabetes" and "non-insulin dependent diabetes") is a disease of glucose metabolism in which the individual becomes resistant to the glucose produced by the pancreas. As a result, glucose is not properly metabolized and serum glucose levels are increased, resulting in numerous complications vascular, renal, neurological and ophthalmological complications as the patient ages. This volume of the Markets...Published: March 1, 2003 | Price: $2,812.00 – $5,625.00
During the last 25 years, there have been unprecedented advancements in the area of women’s health and there is widespread recognition of the importance of addressing conditions that overwhelmingly affect women. Likewise, pharmaceutical marketers have increasingly understood the potential that the women’s health market represents and the increasing clout female consumers are wielding in the prescription drug marketplace. Women’s Health: Worldwide Prescription Drug Markets is a comprehensive study of the pharmaceutical markets aimed at diseases and conditions that affect women....Published: November 25, 2015 | Price: $1,396.50 – $2,796.50
Transdermal and Transmucosal Drug Delivery Markets Transdermal and Transmucosal Drug Delivery Markets analyzes the current and potential markets for transdermal/transmucosal drug delivery, a well-established accepted route of administration for therapeutically beneficial medicines. Transdermal and Transmucosal Drug Delivery Markets provides the following market information: The Worldwide Market for Transdermal/Transmucosal Drug Delivery Technology and Pharmaceuticals, 2013-2020 The Worldwide Market for Pharmaceuticals Utilizing Transdermal/Transmucosal Drug Delivery Systems by Type, 2013–2020 The Worldwide Market for Pharmaceuticals Utilizing Transdermal/Transmucosal Drug Delivery Technologies, Market Share by...Published: May 1, 2007 | Price: $2,700.00 – $5,990.00
This third volume of Kalorama Information’s World Market for Anti-Infectives series, the 2nd. Edition focuses on three general product segments of antiviral treatment: Nucleoside Analogs Protease Inhibitors Other Misc. Antivirals The report covers both currently marketed and late stage development antiviral products in detail. For each segment, the report provides: Revenue Data by Infection Type An overview of products on the market Review of products in the development pipeline Market estimates and forecasts through 2011 Market segmentation by geographic region...Published: October 1, 2003 | Price: $2,625.00 – $5,250.00
Growth factors are gene products that play important roles in the regulation of cell division and tissue proliferation. Generally, the binding of a growth factor to its receptor initiates or, in some cases, blocks the ability of cells to divide and multiply. The nature and mode of action of these substances have made them of great interest in various therapeutic areas for which efficacy and specificity must go hand in hand. This report analyzes the world markets for growth factors,...Published: August 1, 2003 | Price: $2,625.00 – $5,250.00
This Kalorama Information report—Men’s Health: The World Market for Current and Emerging Drug Therapies—focuses on treatment segments in which men are affected. These segments include: · Men’s Cancer · Sexual Function · Sexually Transmitted Diseases · Urinary Conditions · Andropause The report covers drugs that are used for the treatment of conditions affecting men, including prostate cancer, impotence, and BPH; and areas where diseases and men’s health are a major concern including HIV, herpes, and urinary incontinence. Revenues for product...Published: July 18, 2003 | Price: $2,625.00 – $5,250.00
Drug delivery technologies continue to be a vital piece of the pharmaceutical marketing puzzle. From clinical efficacy to product differentiation and life-cycle management, delivery technologies are increasingly demanding the attention of developers at earlier and earlier stages. In Kalorama’s 2001-2002 Drug Delivery series, we focused on the markets by route of administration—oral, injectable, implantable, pulmonary, transdermal etc. In this all new study on advanced drug delivery, however, we focused on drug delivery through the lens of therapeutic application. This report...Published: May 1, 2003 | Price: $2,625.00 – $5,250.00
Switching dosages and ingredients of prescription medicines to the over-the-counter market is not new. In the past 30 years, more than 70 switches have produced hundreds of brands competing in the consumer market, and the pace promises to accelerate. Going OTC is one of a number of strategies marketers can use to extend the revenue life of their products. Appropriately coordinating the switch with patent expiry, creating coherent branding strategies, and knowing the clinical consumer climate are all factors in...Published: June 13, 2013 | Price: $2,500.00 – $5,000.00
In recent years, there has been a substantial increase in the number of drugs available to treat rare ("orphan") diseases. This comprehensive report, The World Market for Orphan Drugs, looks at this trend and provides estimates for the market opportunity in the U.S., Europe, Japan and globally. With over 400 pages of market analysis and over 120 figures and tables, the report provides in-depth coverage of key competitors and important trends and challenges for makers of orphan drug treatments. Osteoporosis,...Published: August 3, 2012 | Price: $2,500.00 – $5,000.00
What Will the Pharma Industry Look Like in 5 Years? There are an estimated 724 projects in development from the top 50 pharmaceutical companies. Together, they have the potential to add billions in value to the current pharmaceutical market in the next five years. What types of drugs are companies developing and what will be the impact of these products on the marketplace and key competitors? In this report, Kalorama Information has analyzed the late-stage R&D pipeline of the...Published: February 1, 2012 | Price: $2,500.00 – $5,000.00
Vaccines are among the top revenue earners in recent years, and in some cases have assisted major pharmaceutical companies to revenue growth. But this is not without some trade-offs. Vaccines involve a complex production process. Is vaccine-making profitable? How much is the industry spending? How much is handed off to other companies and how much is made by the branded manufacturers? How many doses are produced by the industry? These are the type of questions that Kalorama Information has taken...Published: December 1, 2010 | Price: $2,500.00 – $5,000.00
Drug delivery is evolving at a rapid rate with new drug product formulations being discovered frequently. Advanced drug delivery deals with developing solutions for new entities in therapeutic pharmacology such as protein and peptides and other novel compounds targeting drugs to specific disease sites including gene therapy. Treatments for chronic conditions and growth in patient-administered drugs are factors leading to greater focus on ease-of-use and convenience. Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) details the types of drug...Published: July 1, 2007 | Price: $2,500.00 – $5,000.00
An understanding of the market for anesthesia could be worthwhile to any pharmaceutical marketer and any equity company investing or consulting in this area. Anesthesia markets are in one sense simple: growth in these drugs are correlated to prevalence and incidence in disease, and the resulting increase in procedure volumes. But as this market continues to grow, increased competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas of the world. New...Published: March 1, 2007 | Price: $2,500.00 – $5,990.00
Over one billion people suffer from fungal infections worldwide, and this number is growing Though Athlete's foot, dandruff, vaginal yeast infection and fungal nail make up the bulk of these cases, there has been a steady increase in the incidence of more serious infections. This is partially due to the widespread use of antibiotics, which eliminate or decrease fungi-killing bacteria. The increased number of individuals with reduced immune responses caused by AIDS or the effects of chemotherapy has also been...Published: February 1, 2007 | Price: $2,500.00 – $7,990.00
With over 6,160 individual data points reflecting useful market data, Kalorama's Cancer Therapeutics: The Worldwide Market, 2nd Edition is the most comprehensive and recent information available on the five key cancer therapy and treatment markets in a syndicated market research report, including the following areas: Chemotherapy, including -Subcategories Alkylating Agents, Antimetabolites, Cytotoxic Agents, Plant Derivatives -Brands such as Elotaxin, Taxotere, Gemzar, Alimta and Temodar with Market Share for each Hormone Therapy: -Subcategories include Corticosteroids, Hormone Agonists/Antagonists, Aromatase Inhibitors and SERMS...Published: April 1, 2006 | Price: $2,500.00 – $7,000.00
The landscape of generic companies is changing: their relative might in the industry is increasing and the product lines their offering are growing in depth and breadth. Strong growth in the sector has come not only from more aggressive tactics and better acceptance in the clinical and consumer population, but by the loss of patent protection in the past few years of some huge-name drugs, including Prozac, Zocor, Prilosec, Prevacid, Sporanox, Evista, Flovent, Claritin, Allegra, Diflucan, Zofran, Zoloft, and Pravachol....Published: November 1, 2005 | Price: $2,500.00 – $5,000.00
Some of the biggest-selling biological drugs developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, are set to lose patent protection in the United States in 2005 and soon after. This opens up a market currently worth over $30 billion (and growing at over 10% per year) to generic competition, if—and it’s a big if—the regulatory hurdles for these generics can be overcome. Biogeneric is a new term combining biologic...Published: August 1, 2005 | Price: $2,500.00 – $5,000.00
This market briefing concentrates on the U.S. market for medical nutritional support—in particular, the enteral and parenteral foods. The continuing development of equipment, medical foods, and feeding procedures that secure the nutrition of critically ill patents has greatly improved recovery and survival in select populations. Advances in the effectiveness and safety of nutritional procedures and techniques have evolved from steady improvements, including the use of antibiotic materials, biosensors, wireless communications, and more efficient pumps and controllers. These new developments have...Published: June 1, 2005 | Price: $2,500.00 – $5,000.00
This volume of Kalorama Information’s World Market for Anti-Infectives series focuses on three general product segments of antiviral treatment: Nucleoside Analogs Protease Inhibitors Other Misc. Antivirals The report covers both currently marketed and late stage development antiviral products in detail. For each segment, the report provides an An overview Description of products on the market Description of products in development Market estimates and forecasts through 2009 Market segmentation by infection type Market segmentation by geographic region Market share of leading...Published: May 1, 2005 | Price: $2,500.00 – $5,000.00
For the past 60 years, antibiotic drugs have changed bacterial infections from the life-threatening scourges they once were into eminently treatable conditions. However, the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to traditional agents. As a result, pharmaceutical companies are taking a second look at the antibiotic market, after more than two decades of relative complacency. In addition to the scientific and technical challenges of new antibiotic development, there are significant...Published: April 1, 2005 | Price: $2,500.00 – $5,000.00
In the past 100 years, there has been a steady increase in the incidence of serious secondary systemic fungal infections. One of the factors aiding the spread of fungal disease has been the widespread use of broad-spectrum antibiotics, which eliminate or decrease the non-pathogenic bacterial populations that normally compete with fungi. Another has been the vast increase in populations with with compromised immune response (caused by AIDS or by the action of immunosuppressant drugs or cancer chemotherapy agents). In addition...Published: January 1, 2003 | Price: $2,500.00 – $5,000.00
Antibiotic development has never proceeded at this pace or with this much urgency. Demand for effective antibacterial compounds is growing rapidly and companies are trying to fill their pipelines with products that can meet the challenges of increasingly stubborn infectious agents. By far the largest of the anti-infective segments, antibacterials represent approximately 65% of the $20 billion world market in infectious disease drugs. However, it’s also the most crowded of the segments with big pharma and small biotech companies alike...